Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.97
- Piotroski Score 3.00
- Grade Overweight
- Symbol (RARE)
- Company Ultragenyx Pharmaceutical Inc.
- Price $53.82
- Changes Percentage (-1.82%)
- Change -$1
- Day Low $53.78
- Day High $55.40
- Year High $60.37
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/31/2024
- Fiscal Year End N/A
- Average Stock Price Target $113.00
- High Stock Price Target $150.00
- Low Stock Price Target $67.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$7.95
- Trailing P/E Ratio -5.21
- Forward P/E Ratio -5.21
- P/E Growth -5.21
- Net Income $-606,639,000
Income Statement
Quarterly
Annual
Latest News of RARE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Rainbow Rare Earths Limited's (LON:RBW) top owners are individual investors with 57% stake, while 24% is held by insiders
Rainbow Rare Earths Limited (LON:RBW) has 15 investors with a majority stake of 43%. Individual investors own 57%, insiders 24%. Institutional investors are less involved due to company size or perfor...
By Yahoo! Finance | 17 hours ago -
She was in pain for years, but doctors had no answers. A rare condition was to blame.
Jill Becher suffered from excruciating pain due to glossopharyngeal neuralgia, a rare condition. After failed brain surgery, a risky second surgery successfully relieved her pain, giving her a new lea...
By CBS News | 1 day ago -
Paris Las Vegas' $100 Million Renovation Includes Rare Balcony Rooms
Paris Las Vegas underwent a $100 million renovation to introduce the new Versailles Tower. Led by Klai Juba Wald, the project added over 750 rooms, a pedestrian bridge, and updated corridors, offering...
By Forbes | 1 day ago
